Compositions of long-term action insulins

FIELD: pharmacology.

SUBSTANCE: group of inventions refers to an aqueous pharmaceutical composition containing 270-330 U/ml of glargine insulin [equimolar to 270-330 IU of human insulin], wherein the composition containing 300 U/ml of glargine insulin is excluded, for treatment of type I and II diabetes.

EFFECT: application of these inventions allows to provide a basal insulin reserve within 24 hours after a subcutaneous injection of a single dose.

16 cl, 9 dwg, 12 tbl, 18 ex

 



 

Same patents:

FIELD: medicine.

SUBSTANCE: integrated resort treatment is conducted. A patient takes carbonic sodium chloride mineral water. The mineral water is heated to a temperature of 37°C before use and taken at 3 ml per 1 kg of body weight 3 times a day 40 minutes before meals. The therapeutic course makes 18 days. The patient also takes "dry" carbon dioxide baths with the CO2 concentration of 1.2-1.4 g/l at the water temperature of 35°C. The water temperature is reduced to 32°C by the end of the course. The procedure length is 15-20 minutes. CO2 is supplied from a balloon into a special box compartment at a rate of 15-20 l/min. The gas mix temperature ranges from 28°C to 38°C. The procedures are performed every second day. The course of 8-10 procedures is required.

EFFECT: method provides normalising the complete blood count, blood sugar, common urine analysis, improving the visual analysis health, renal blood flow, ophthalmic parameters by the integrated intake of mineral water and dry carbon dioxide baths, optimum regimen and length of the therapeutic course.

1 ex

FIELD: chemistry.

SUBSTANCE: invention relates to biotechnology, specifically to novel analogues of a glucagon-like peptide, and can be used in medicine to activate insulin expression in mammals and to treat sugar diabetes.

EFFECT: obtained peptide derivatives have a peptide imitating linker and provide prolonged action when treating diabetes and other diseases associated with insulinotropic peptides, gastrointestinal functions and glucagon levels.

25 cl, 23 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to pharmaceutical composition, which contains compound of insulin in concentration, sufficient for supplying therapeutically effective level of insulin compound in blood plasma for at least 3 days. Insulin compound relates to pro-medical compound, which represents insulin conjugate with linker, bound with hydrogel carrier. Also described is suspension, containing pharmaceutical composition of insulin conjugate, method of suspension obtaining, set, including pharmaceutical composition of insulin conjugate and container for introduction of composition.

EFFECT: pharmaceutical composition of insulin conjugate by invention is characterised by the fact that it has pharmacokinetic profile in vivo in fact without release of insulin compound.

26 cl, 9 dwg, 21 ex

FIELD: medicine.

SUBSTANCE: correcting cognitive disorders in the patients suffering arterial hypertension accompanying type 2 diabetes mellitus is ensured by combining a standard drug therapy with administering the preparation Kudesan 60 mg a day throughout two months.

EFFECT: administering Kudesan in the above dose and regimen provides the effective correction of cognitive disorders in the above group of patients in a combination with improving the cardiovascular function and metabolic processes.

2 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: correcting increased levels of anxiety and depression in the patients with arterial hypertension accompanying type 2 diabetes mellitus is ensured by combining a standard drug treatment and administering Kudesan 60 mg a day for two months.

EFFECT: method provides the effective correction of anxiodepressive conditions in the given category of patients that in turn enables normalising blood pressure more effectively by reducing the negative psychosomatic effect.

1 ex, 2 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to methods of treating type 2 diabetes, insulin resistance, insulin hyposecretion, obesity, hyperglycaemia and hyperinsulinemia, involving administering an effective amount of an anti-IL-1β antibody or its fragment into an individual, as well as to using the anti-IL-1β antibody or its fragment in preparing a composition applicable for treating the above diseases or conditions.

EFFECT: group of inventions is effective in treating type 2 diabetes mellitus, insulin resistance, insulin hyposecretion, obesity, hyperglycaemia and hyperinsulinemia.

67 cl, 13 dwg, 5 tbl, 14 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to novel N-containing heteroaryl derivatives of formula I or II or their pharmaceutically acceptable salts, which possess properties of JAK kinase, in particular JAK3, and can be applied for treating such diseases as asthma and chronic obstructive pulmonary disease (COPD). In formulae A represents carbon and B represents nitrogen or A represents nitrogen and B represents carbon; W represents CH or N; R1 and R2, independently represent hydrogen, C1-4alkyl, halogenC1-4alkyl, -CN; R3 represents C1-4alkyl, R9-C1-4alkyl, Cy1, where Cy1 is optionally substituted with one or several substituents R10; R4 represents hydrogen, C1-4alkyl, R12R7N-C0alkyl, where one of R7 and R12 represents hydrogen, and the other represents C1-4alkyl or group R13, which is selected from C1-5alkyl, Cy2-C0alkyl; R5 represents hydrogen; R6 represents hydrogen, C1-4alkyl, C1-4alkoxyC1-4alkyl, hydroxyC1-4alkyl, R12R7N-C1-4alkyl, R16CO-C0alkyl, Cy1; R7 represents hydrogen or C1-4alkyl; R9 represents halogen, -CN, -CONR7R12, -COR13, CO2R12, -OR12, -SO2R13, -SO2NR7R12, -NR7R12, -NR7COR12; R10 represents C1-4alkyl or R9-C0-4alkyl; R11 represents C1-4alkyl, halogen, -CN, -NR7R14; R12 represents hydrogen or R13; R13 represents C1-5alkyl, hydroxyC1-4alkyl, cyanoC1-4alkyl, Cy2-C0alkyl or R14R7N-C1-4alkyl; where Cy2 is optionally substituted with one or several constituents R11; R14 represents hydrogen or C1-4alkyl; R16 represents C1-4alkyl, halogenC1-4alkyl, C1-4alkoxyC1-4alkyl, hydroxyC1-4alkyl or cyanoC1-4alkyl; Cy1 represents monocyclic carbocyclic unsaturated or saturated ring, selected from C3-C6cycloalkyl, phenyl, or saturated monocyclic 4-6-membered heterocyclic ring, containing from 1 to 2 heteroatoms, selected from N and S, or partially unsaturated 10-membered bicyclic heterocyclic ring, containing oxygen atom as heteroatom, which can be substituted with group R11, where said ring is bound with the remaining part of molecule via any available C atom, and where one or several ring C or S atoms are optionally oxidised with formation of CO or SO2; and Cy2 represents monocyclic carbocyclic unsaturated ring, selected from C3-C6cycloalkyl, or aromatic monocyclic 4-6-membered heterocyclic ring, containing from 1 to 2 heteroatoms, selected from N and S, or unsaturated 10-membered bicyclic heterocyclic ring, containing oxygen atom as heteroatom, which can be substituted with group R11, where said ring is bound with the remaining part of molecule via any available atom C or N.

EFFECT: obtaining novel heteroaryl derivatives.

27 cl, 41 ex

Transdermal plaster // 2553350

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine. Described is matrix layer, suitable for application in plaster for transdermal delivery, aimed at introduction of biologically active compounds, which includes phosphate compound of tocopherol and polymer carrier. Also described is transdermal plaster and method of its production.

EFFECT: plaster makes it possible to efficiency introduce biologically active compounds.

48 cl, 15 tbl, 13 dwg, 12 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry and represents clinical nutrition for prevention, treatment or relief of one or several symptoms, associated with impairment of metabolism or its disorder, which contains composition of polysaccharide high-viscosity dietary fibre, including viscous fibre mixture or its complex, consisting of from 48% to 90% in wt % of glucomannan, from 5 to 20 % in wt % of xanthan gum and from 5% to 30% in wt % of alginate, as well as, at least, one macroelement, selected from the group, consisting of protein carbohydrate and fat, where clinical nutrition is composed in order to provide dose of composition of polysaccharide high-viscosity dietary fibre from 20 g/day to 35 g/day for time period, effective for prevention, treatment and relief of one or several symptoms, associated with impairment of metabolism or its disorder.

EFFECT: invention ensures extension of arsenal of means, preventing, relieving or treating one or several symptoms, associated with impairment of metabolism or metabolic disease.

14 cl, 6 ex, 20 tbl, 48 dwg

FIELD: medicine.

SUBSTANCE: patients with diabetic microangiopathy are subjected to an examination which includes: general blood test, blood sugar, general urine analysis, ultrasonic examination of kidneys with the determination of indices of the kidney blood flow (Vmax, Vmin, S/D, PI, RI), basic ophthalmological parameters (vision acuity, examination of eye fundus vessels). Then, the intake of mildly-mineralised hydrocarbonate-chloride-sodium mineral water "Obyhovskaya" directly from the spring under sanatorium conditions is administered. Water is taken in heated to a temperature of 37°C in a dose of 3 ml per 1 kg of body weight 3 times per day 40 minutes before meal, the course constitutes 18 days.

EFFECT: application of the invention makes it possible to normalise the general blood test, blood sugar, general urine analysis, improve the condition of the visual analyser and indices of the kidney blood flow.

1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to pharmaceutical composition, which contains compound of insulin in concentration, sufficient for supplying therapeutically effective level of insulin compound in blood plasma for at least 3 days. Insulin compound relates to pro-medical compound, which represents insulin conjugate with linker, bound with hydrogel carrier. Also described is suspension, containing pharmaceutical composition of insulin conjugate, method of suspension obtaining, set, including pharmaceutical composition of insulin conjugate and container for introduction of composition.

EFFECT: pharmaceutical composition of insulin conjugate by invention is characterised by the fact that it has pharmacokinetic profile in vivo in fact without release of insulin compound.

26 cl, 9 dwg, 21 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to the field of biotechnology, namely to obtaining insulin analogues, and can be used in medicine as a medication for reducing the glucose level in a patient's blood. An insulin analogue contains a polypeptide B-chain, including halogenated phenylalanine in B24 position, which provides an increased stability in comparison with non-halogenated insulin or insulin analogue. Halogenated phenylalanine represents ortho-monofluorophenylalanine, ortho-monobromophenylalanine or ortho-monochlorophenylalanine.

EFFECT: halogenation-conditioned insulin stabilisation makes it possible to simplify the treatment of patients with diabetes mellitus in developing countries, where there is no access to refrigerating equipment.

11 cl, 8 dwg, 7 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the pharmaceutical industry and represents a formulation specially adapted for insulin transformation into the aerosol state, containing insulin in water from 100 IU/ml to 1,200 IU/ml and 2 to 4 Zn2+ ions per the insulin hexamer, wherein the formulation is preservative-free and wherein the formulation is able to transform into the aerosol state as an aerosol spray when using a holed vibration plate with no foaming of the formulation, when the formulation is kept on a back surface of the holed plate by gravity, and the spray is ejected from the front surface of the holed plate entirely by vibrating the holed plate.

EFFECT: invention provides reducing the foaming of the formulation, the time of transformation into the aerosol state and providing the more effective administration of an insulin dose.

19 cl, 5 dwg

FIELD: medicine.

SUBSTANCE: invention refers to a method of treating a condition or a disease, wherein the insulin administration is considered to be effective; the method involves administering effective doses of an insulin derivative representing insulin NεB29-(Nα-(HOOC(CH2)14CO)-y-L-GIu) des(B30) into a patient in need thereof, wherein the above insulin derivative has a prolonged time-action profile, and the above doses are to be administered every 24 to 336 hours.

EFFECT: treating by administering the above insulin through extended intervals of time and simplifying the therapeutic regimens for patient's comfort.

11 cl, 4 ex, 5 tbl, 3 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to pharmaceutics, namely to an aqueous pharmaceutical composition containing insulin, an insulin analogue or an insulin derivative and methionine; as well as to a method for preparing and using it for treating diabetes mellitus, and to a therapeutic agent for treating diabetes mellitus.

EFFECT: group of inventions provide stability of the above proteins in solution.

29 cl, 10 ex, 6 dwg

FIELD: medicine, pharmacology.

SUBSTANCE: group of the inventions relates to the field of pharmaceutics and medicine and concerns a liquid composition containing the agonist GLP-1 and/or its pharmacologically acceptable salt, insulin glargin and/or its pharmacologically acceptable salt and, optionally, at least one pharmacologically acceptable auxiliary substance characterized by that the given composition contains methionine and has pH value from 3.5 up to 5. Also the combination of compositions, set containing a combination, and the use for obtaining of medicinal preparation for treatment of pancreatic diabetes are offered.

EFFECT: group of inventions ensures the storage stability and chemical integrity of active components.

27 cl, 2 ex, 4 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to treating diabetes. That is ensured by the method for transdermal administration of insulin. The method involves placing a flat applicator pre-soaked in an insulin solution in the form of a porous titanium nickelide plate of the thickness of 0.2 to 1 mm on skin. The plate and skin are heated by an infrared light source, while a procedure length is specified within 30 to 120 minutes. A device used for implementing the method comprises a body with a power supply, a heating element and the flat applicator pre-saturated with insulin. The applicator represents the removable porous titanium nickelide plate of the thickness of 0.2 to 1 mm forming one of the body walls. The heating element is represented by the infrared light source in the form of a light-emitting diode set integrated into the body above the plate.

EFFECT: invention provides the more comfortable procedure by eliminating injuring factors, simplifying the power supply configuration, as well as making the applicator process more ordinary, including a possibility to implement the process in everyday life.

2 cl, 1 ex, 3 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutics and medicine, and concerns an injectable insulin preparation for reducing an individual's blood glucose level. The preparation contains an insulin compound, a nicotinic acid compound and arginine.

EFFECT: invention provides the fast absorption of the insulin compound, a possibility to administer the preparation closer to a meal, as well as reduces a risk of hypoglycemia following meals.

14 cl, 5 dwg, 3 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: group of inventions concerns a kit for treating diabetes comprising the first pharmaceutical composition and the second pharmaceutical composition, wherein the first pharmaceutical composition contains Gly(A21)-Arg(B31)-Arg(B32) human insulin, and the second pharmaceutical composition contains Gly(A21)-Arg(B31)-Arg(B32) human insulin and desPro36exendin-4(1-39)-Lys6-NH2; using the kit for preparing a medicated product for treating a patient suffering from diabetes for controlling the blood glucose concentration on an empty stomach, after meals and/or after absorption, or for improving the glucose tolerance.

EFFECT: group of inventions enables achieving the synergetic effect of the combination of the above compounds.

13 cl, 14 ex, 10 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to the field of biotechnology, namely to novel analogues of insulin and can be used in medicine. The said insulin analogue is characterised by one of the following structures: Arg(A0), His(A8), Gly(A21), Arg(B31), Arg(B32)-NH2-insulin; His(A8), Gly(A21), Arg(B31), Arg(B32)-NH2-insulin; Arg(A0), Glu(A15), His(A8), Gly(A21), Arg(B31), Arg(B32)-NH2-insulin. The invention also relates to a method of obtaining the said analogue, a pharmaceutical composition and a medication, including its application for treatment of diabetes mellitus.

EFFECT: invention makes it possible to obtain the insulin analogue, characterized by the delayed release and steady and longer action, for instance, in comparison with human insulin or glargine insulin.

18 cl, 2 dwg, 24 ex

FIELD: medicine.

SUBSTANCE: method involves taking lavage fluid samples from injured bronchi in preoperative period in making fiber-optic bronchoscopy examination. Microflora colonizing bronchial mucous membrane and its sensitivity to antibiotics is determined. Therapeutic dose of appropriate antibiotic and therapeutic dose of immunomodulator agent like leykinferon is introduced in endolymphatic way 40-60 min before operation. Smears are taken from outlying bronchi in doing operation. Sputum or fluid in retained pleural cavity are taken in 1-2 days after the operation. Prophylaxis effectiveness is determined on basis of bacteriological study data. Therapeutic dose of antibiotics and leykinferon are introduced in 6-8 and 20-24 h after the operation in endolymphatic way. The preparations are introduced at the same doses in endolymphatic way making pauses depending on selected antibiotic elimination half-time once or twice a day until the drains are removed mostly during 48-72 h after operation.

EFFECT: enhanced effectiveness of antibacterial protection; high reliability of antibiotic prophylaxis.

Up!